Avalo Therapeutics (AVTX) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 24.1% versus a gain of 0.7%. Over five years, SLDB leads with a -79.7% price change compared with -99.8% for AVTX. Solid Biosciences is the larger company by market cap ($728.1 million vs $709.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | SLDB |
|---|---|---|
| Share price | $13.23 | $6.79 |
| Market cap | $709.52M | $728.06M |
| 1-day change | -2.58% | -0.88% |
| YTD return | -25.22% | +21.45% |
| 1-year return | +0.74% | +24.09% |
| 5-year return | -99.79% | -79.70% |
| EPS (TTM) | $-4.31 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $11.45 |
| 52-week low | $12.51 | $3.79 |
| Distance from 52-week high | -45.49% | -40.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +233.18% | +174.23% |
| Average volume | 926.15K | 1.09M |
| Shares outstanding | 53.63M | 107.23M |
| Employees | 33 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed AVTX by 23.4 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
AVTX vs SLDB FAQ
Which is bigger, Avalo Therapeutics or Solid Biosciences?
Solid Biosciences (SLDB) is larger, with a market capitalization of $728.06M compared with $709.52M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or SLDB?
SLDB returned +24.09% over the past 12 months, compared with +0.74% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Solid Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Avalo Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Solid Biosciences.